Ribera Alba, Benavent Eva, Lora-Tamayo Jaime, Tubau Fe, Pedrero Salvador, Cabo Xavier, Ariza Javier, Murillo Oscar
Infectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, Barcelona, Spain
Infectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, Barcelona, Spain.
J Antimicrob Chemother. 2015 Dec;70(12):3357-65. doi: 10.1093/jac/dkv281. Epub 2015 Sep 28.
In the era of emergence of MDR Pseudomonas aeruginosa, osteoarticular infections (OIs) add more difficulties to its treatment. The role of β-lactams (BLs) is questioned and older drugs need to be reconsidered. The objective of this study was to describe our experience in the management of OIs caused by MDR P. aeruginosa and evaluate different therapeutic options.
This was a retrospective analysis of a prospectively collected cohort (2004-13) of patients with OI caused by MDR P. aeruginosa. We created two groups: (i) Group A (more difficult to treat), prosthetic joint infections (PJIs) and osteoarthritis (OA) managed with device retention; and (ii) Group B (less difficult to treat), OA managed without device retention. Antibiotic treatment was administered according to clinician criteria: monotherapy/combined therapy; and BL used by intermittent bolus (IB)/continuous infusion.
Of 34 patients, 15 (44.1%) had PJI and 19 (55.9%) had OA (8 related to an orthopaedic device). Twenty-three cases (68%) were caused by XDR P. aeruginosa. The initial management included removal of an orthopaedic device in 14 cases, together with antibiotic [alone, 19 (55.9%; 4 colistin, 14 BL-IB and 1 BL continuous infusion); and in combination, 15 (44.1%; 5 BL-IB and 10 BL continuous infusion)]. The overall cure rate was 50% (39% and 63% in Groups A and B, respectively), ranging from 31.6% with monotherapy to 73.3% with combined therapy (P = 0.016), with special interest within Group A (cure rate with combined therapy 71.4%, P = 0.049). After rescue therapy, which included removal of remaining devices, the cure rate reached 85.3%.
We suggest that the BL/colistin combination is an optimized therapy for OI caused by MDR P. aeruginosa, together with an appropriate surgical treatment.
在多重耐药铜绿假单胞菌出现的时代,骨关节炎感染(OIs)给其治疗增加了更多困难。β-内酰胺类药物(BLs)的作用受到质疑,需要重新考虑使用较老的药物。本研究的目的是描述我们在治疗多重耐药铜绿假单胞菌引起的骨关节炎感染方面的经验,并评估不同的治疗选择。
这是一项对前瞻性收集的队列(2004 - 2013年)中多重耐药铜绿假单胞菌引起的骨关节炎感染患者进行的回顾性分析。我们创建了两组:(i)A组(治疗难度较大),假体关节感染(PJIs)和采用保留装置治疗的骨关节炎(OA);(ii)B组(治疗难度较小),未采用保留装置治疗的骨关节炎。抗生素治疗根据临床医生的标准进行:单一疗法/联合疗法;β-内酰胺类药物采用间歇推注(IB)/持续输注。
34例患者中,15例(44.1%)患有假体关节感染,19例(55.9%)患有骨关节炎(8例与骨科器械有关)。23例(68%)由广泛耐药铜绿假单胞菌引起。初始治疗包括14例患者取出骨科器械,同时使用抗生素[单独使用,19例(55.9%;4例使用黏菌素,14例使用β-内酰胺类药物间歇推注,1例使用β-内酰胺类药物持续输注);联合使用,15例(44.1%;5例使用β-内酰胺类药物间歇推注,10例使用β-内酰胺类药物持续输注)]。总体治愈率为50%(A组和B组分别为39%和63%),单一疗法的治愈率为31.6%,联合疗法为73.3%(P = 0.016),A组特别值得关注(联合疗法治愈率为71.4%,P = 0.049)。在包括取出剩余器械的挽救治疗后,治愈率达到85.3%。
我们建议β-内酰胺类药物/黏菌素联合疗法是治疗多重耐药铜绿假单胞菌引起的骨关节炎感染的优化疗法,同时进行适当的手术治疗。